Skip to main content
. 1999 Nov 23;96(24):13983–13988. doi: 10.1073/pnas.96.24.13983

Figure 2.

Figure 2

Western blot analyses by using a panel of anti-ATRX antibodies. (a) Nuclear extracts from EBV-transformed lymphocytes probed with polyclonal (FXNP5) and monoclonal (71f, 39f, 23c, and 38d) antibodies. An antibody against TAF II p250 was used as a control. Lanes: N, normal individual; 1, ped. 26; 2, ped. N29. (b) Nuclear extracts from EBV-transformed lymphocytes probed with the anti-ATRX antibody 39f. Annotations are as above; 3, ped. 12; 4, ped. 10 (II-3). (c) Nuclear extracts probed with anti-ATRX antibody 23c and anti-TAF II p250. Annotations are as before; 5, ped. 10 (II-2); 6, ped. 58; 7, ped. 59 (III-10); 8, ped. 59 (III-1); 9, ped. N1 (III-5); 10, ped. N1 (III-4); 11, ped. 38; 12, ped. 17; 13, ped. 27. Arrows indicate: A, full-length ATRX protein; T, TAF II p250; Tr, truncated ATRX protein.